Analysis of the TAX1BP1 gene in head and neck cancer patients  by Ruiz, Mariangela Torreglosa et al.
193
Brazilian Journal of otorhinolaryngology 76 (2) March/april 2010
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Analysis of the TAX1BP1 gene 
in head and neck cancer 
patients
   Summary
Mariangela Torreglosa Ruiz 1, Janayna Fernanda 
Balachi 2, Raquel Aldrighi Fernandes 3, Ana Lívia 
Silva Galbiatti 4, José Victor Maniglia 5, Érika 
Cristina Pavarino-Bertelli 6, Eny Maria Goloni-
Bertollo 7
 1 PhD in Health Sciences. Biologist - Genetics and Molecular Biology Unit - Medical School - São José do Rio Preto - FAMERP.
 2 Bachelor in Biology - UNESP São José do Rio Preto, Biologist.
 3 Medical Student - Medical School - São José do Rio Preto - FAMERP.
 4 Bachelor in Biology - UNORP - São José do Rio Preto, MSc in Health Sciences - Medical School - São José do Rio Preto.
 5 Associate Professor - Otolaryngology and Head and Neck Surgery, Adjunct Professor - Otorhinolaryngology and Head and Neck Surgery.
 6 Associate Professor in Human Genetics; MD; Adjunct Professor - Molecular Biology Department - Medical School -São José do Rio Preto - FAMERP.
 7 Associate Professor in Human Genetics; MD. Adjunct Professor - Medical School - São José do Rio Preto - FAMERP.
Unidade de Pesquisa em Genética e Biologia Molecular - UPGEM - Av. Brigadeiro Faria Lima 5416 bloco U-6 São José do Rio Preto 15090-000.
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) e Centro Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Paper submitted to the BJORL-SGP (Publishing Management System – Brazilian Journal of Otorhinolaryngology) on April 28, 2009; 
and accepted on November 24, 2009. cod. 6383
In Brazil, there were 14,160 new estimated cases of head and 
neck cancer for the year of 2008. Smoking and drinking are 
the main risk factors established in the etiology of this disease. 
Aim: to assess the T → A polymorphism in gene TAX1BP1 
(leu306ile) in patients with head and neck cancer and a 
control population. Series and methods: a retrospective 
study in which we assessed the gender, age, smoking and 
drinking habits of 191 patients with head and neck cancer and 
200 individuals without history of neoplasia. The molecular 
analysis was carried out after genomic DNA extraction by 
the PCR-RFLP method. Results: there is a predominance of 
males (84.82%), smokers (91.1%) and drinkers of alcohol 
(77.49%). Molecular assessment did not show statistically 
significant differences between the two groups (p =0.32). The 
analysis of clinical parameters and polymorphisms showed 
association with oral cavity cancer (OR: 2.38; CI 95%: 1.18-
4.78; p = 0.01), the other parameters were not associated 
with the polymorphism. Conclusion: There is evidence of 
association between TAX1BP1 gene polymorphism and oral 
cavity cancer. For the remaining parameters analyzed, the 
results do not suggest association with the TAX1BP1 gene 
polymorphism.
Keywords: alcohol drinking, genetics, head and neck 
neoplasms, tobacco.
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INTRODUCTION
Malignant neoplasia of the head and neck is a term 
associated with tumoral lesions located in the oral cavity 
(40%), pharynx (15%), larynx (25%), and other places - 
such as the salivary glands (20%)1,2. The most frequent 
histological type is the squamous cell carcinoma, present 
in more than 90% of the cases3,4. This type of cancer is 
characterized by a major local aggressiveness, recurrence. 
About 2/3 of the patients have the disease in advanced 
stages, commonly involving the regional lymph nodes. 
Distant metastasis happened to 10% of the patients5,6.
In Brazil, according to the National Cancer Institute 
(NCI), the incidence of oral cancer - the most representa-
tive among these types of tumor, was estimated in 14,160 
new cases in 20087.
Smoking and drinking are the main risk factors 
associated with head and neck cancer. Epidemiological 
studies have shown that each one of these factors sepa-
rately increases the risk of developing neoplasia in this 
region in three fold, and when associated, the risk goes 
up to be fifteen fold8-10.
Single nucleotide polymorphisms (SNPs) are the 
most common type of variation in the human genome 
and correspond to DNA polymorphisms affecting one 
single nucleotide, with a frequency higher than 1% in 
humans11-14. An ever larger number of these alterations 
is being associated to the molecular bases of diseases 
involving a genetic component, such as cancer, or as a 
risk factor for acquired diseases14.
Numerous haplotypes and genetic polymorphisms 
involved in the metabolism of drugs, transportation and 
action mechanisms have been investigated in order to 
optimize treatment response, such as C677T and A1298C 
polymorphisms of the methylenetetrahydrofolate reductase 
(MTHFR)gene15.
In this study, we assessed the role of a single nucle-
otide polymorphism T → A, in the development of head 
and neck carcinoma, present in gene TAX1BP1, described 
by Brentani et al. in 200316. This gene is a marker of inte-
rest for the study for having been selected in an unbiased 
library (Cancer Human Genome Project), which passed 
through a first validation stage17.
Gene TAX1BP1 produces Human T-cell leukemia 
virus type I binding protein 1, and is located in chromoso-
me 7p15 and has a T → A polymorphism resulting in the 
substitution of Leucine (leu) for Isoleucine (ile) in position 
306 of the protein18. It was identified for the first time as 
a target of the Tax protein from virus of the human T cell 
leukemia20. TAX1BP1 also interacts with other important 
molecules such as A20 and TRAF6, which participate in 
inflammatory response processes19,20.
Thus, the goal of the present paper was to identify 
the T → A polymorphism, which results in the substitution 
of aminoacid Leucine (leu) for Isoleucine (ile) in position 
306 of the protein from gene TAX1BP1 in patients with 
head and neck cancer and in a population of individuals 
without a past of neoplasia and also to assess the distri-
bution of these genotypes  according with the clinical 
and pathological characteristics of head and neck cancer.
MATERIALS AND METHODS
This study was approved by the Ethics in Research 
Committee of the institution under protocol # 5566/2005.
In this paper we analyzed 191 patients with head 
and neck cancer and 200 individuals without a past of 
neoplasia. All the samples were obtained after free and 
informed consent from all the participants. We analyzed 
the social and demographic profile of these patients (age 
and gender) and the exposure to risk factors (smoking 
and drinking). Information about smoking and drinking 
was limited regarding the use or not of smoke and alcohol 
beverages. Those individuals who smoked about 100 ci-
garettes during their entire lives were considered smokers 
and those who had more than four drinks per week were 
considered alcoholics21,22. In the group of patients we in-
cluded those individuals with a histopathological diagnosis 
of head and neck squamous cell carcinoma. In the control 
group we included individuals from outpatient wards of 
other medical specialties, as exclusion criteria we inves-
tigated the individual’s cancer family history, ruling out 
the cases of neoplasias. We used 60 months as follow up 
time for controls and patients.
Among patients, we analyzed the primary sites of 
tumor occurrence and the tumors were classified accor-
ding to the parameters of the Union International Control 
Cancer (IUCC), 2002 and the American Joint Committee 
for Cancer (AJCC), 2002, in three criteria: tumor size (T), 
compromised regional lymph nodes present (N) and the 
presence of distant metastases (M)23,24.
Genomic DNA was extracted from peripheral 
blood25. For molecular evaluation, we used the PCR-RFLP 
method. In order to identify the polymorphic alleles we 
used polymerase chain reactions (PCR) in a total volume 
of 20 µl, using 50 ng of genomic DNA, 0.3mM of sense 
primer (5’ - ACCTGGGTCTCCTAAATCCT - 3’), 0.3 mM of 
antisense primer (5’ - AGCCTG CCAATCTCTTCTT - 3’), 
200mM dNTP, 1X reaction buffer, 1.5mM MgCl2, 0.2 units 
of  Taq polymerase. The PCR amplification was carried out 
through an initial denaturation stage at 95°C, followed by 
35 cycles of denaturation at 95°C for 30 seconds, annealing 
at 57°C, extension at 72°C for 30 seconds and final exten-
sion stage at 72°C. The PCR products were visualized in 
1.5% agarose gel, dyed with ethidium bromide. 
The amplification products were submitted to en-
zyme digestion with Apo I restriction endonuclease and 
this digestion product was submitted to a 2% agarose gel 
electrophoresis at 80 V for 4 hours in order to observe the 
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migration pattern among the size fragments. Polymorphism 
destroys the restriction site, and the amplified 264 pb is 
not cut. In the absence of polymorphism, the product is 
digested in two fragments (one fragment of 205 pb and 
another fragment of 59 pb).
For the statistical analysis, the demographic data was 
plotted by descriptive analysis and compared through the 
Fisher’s Exact Test. This test was also used for the statis-
tical analysis of the genotypic and allelic polymorphism 
distribution.
The multiple logistic regression models were used in 
order to determine the effect of the variables analyzed in 
head and neck cancer. The model included age (reference: 
< 52 years, median of the two groups), gender (reference: 
female), smoking (reference: non-smokers) and drinking 
habits (reference: not a drinker).
The clinical-pathological characteristics were also 
analyzed by multiple logistic regressions. T classification 
was broken down in small tumors (T1,T2) and larger 
ones (T3, T4The N classification was dichotomized into 
negative lymph node involvement (N0), and positive (N1, 
N2, N3). Stages were broken down into early (stages I, II) 
and advanced disease (III and IV).
The results were presented in odds ratio (OR) and 
95% confidence interval (CI - 95%). The level of signifi-
cance was established in 5% (p=0.05).
The Kaplan-Meier method was employed in order 
to assess different disease survival and recurrence rates 
among the different genotypes and the Log-Rank test was 
used in order to assess these differences between geno-
types. For the survival analysis we considered as end point 
the period comprehended between disease diagnosis and 
death, and for the recurrence analysis, the end point was 
the recurrence diagnosis.
RESULTS
Table 1 shows the demographic data of the 191 
patients with head and neck cancer and the 200 indi-
viduals without a past of neoplasias. The mean age of 
patients with head and neck cancer was 58 years, with 
a standard deviation of ± 9.69. We used a control group 
(individuals without a history of neoplasia) with mean 
age of 47 years, with a standard deviation of ± 15.69. The 
statistical analysis for this variable was significant between 
the groups (p< 0.0001). The median age of patients and 
controls was 42 years.
As far as gender is concerned, 84.82% of the patients 
were males and 15.18% were females. The frequency found 
in the control group was 76.5% of males and 23.5% fema-
les. The statistical analysis showed significance between 
these two groups (p= 0.04).
In relation to smoking and drinking habits, the infor-
mation was limited to whether or not the person smoked or 
drank alcohol. In the group of patients with head and neck 
cancer, 91.1% were smokers and 77.49% drank alcoholic 
beverages. Among control individuals, 51% were smokers 
and 51% drank alcoholic beverages. The statistical analysis 
concerning smoking proved significant among the groups 
(p<0.0001), as well as alcohol consumption (p<0.0001). 
The most representative tumor site among patients was 
the oral cavity (30%).
The allele frequencies for the head and neck can-
cer patients were, respectively (T=0.87 and A=0.13) and 
for controls (T=0.90 and A=0.10) not showing statistically 
significant difference between the groups (p=0.32). The 
genotypic frequency (Table 2) also did not show difference 
between the groups (p= 0.3080). The genotypic frequen-
cies are within the Hardy-Weinberg balance between 
patients (X2 = 1.71; p = 0.19) and control groups (X2 = 
0.05; p = 0.81).
Table 1. Demographics of head and neck cancer patients. 
Patients Controls P
# of individuals 191 200
Age (mean ±SD) 58.24±9.69 47.55±15.69 < 0.0001
Gender 0.04
Males 162 (84.82%) 153 (76.5%)
Females 29 (15.18%) 47(23.5%)
Smoking 174 (91.1%) 102 (51%) < 0.0001
Drinking 148 (77.49%) 102 (51%) < 0.0001
SD= Standard Deviation
Table 2. Genotypic distribution of the TAX1BP1 gene T→A polymor-
phism (Genotypes TT: wild homozygote; TA: heterozygote; AA: 
polymorphic homozygote) in head and neck cancer patients and 
controls.
Genotypes Patients n (%)   Controls n (%) p
TT 148 (82,41) 165 (82,41) 0,3080
TA 38 (19,90) 33 (16,58)
AA 5 (2,62) 2 (1,01)
Since it was not possible to pair the demographic 
data with risk factors between patients and controls, we 
carried out the multiple logistic regression in order to 
assess the potential interaction between the genotypes 
studied and the socio-demographic characteristics (age 
and gender) and risk factors (smoking and drinking) (Ta-
ble 3) and there were no differences between the groups 
regarding the characteristics investigated.
The analysis between the polymorphism and the 
clinical parameters is presented on Table 4. Regarding 
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the tumor’s primary anatomical site, the polymorphism 
frequency was greater in the oral cavity cancer (OR = 2.38; 
IC 95% 1.18 - 4.78; p = 0.01). We did not find associations 
regarding tumor extension, lymph node involvement and 
tumor staging. The analysis for the M criterion was not 
carried out since only one patient had the M1 classification.
The Kaplan-Meier curves are presented on Figure 
1, and there were no statistical differences between the 
presence of polymorphism, survival rate (p = 0.4078) and 
the disease recurrence rate (p = 0.8827). For this analysis 
we calculated the presence of recurrence and death after 
the first consultation (disease diagnosis) until the consul-
tation date in the medical chart. Regarding recurrence, 
there was  an average of 27 months and only 02 patients 
(2.11%) died during the analysis period.
Table 3. Demographic data distribution, risk factors, TAX1BP1 genotypes (genotypes TT: wild homozygote; TA: heterozygote; AA: polymorphic 
homozygote) in odds ratio (OR) for the head and neck cancer.
Variables TT (Patients/Controls) OR (CI 95%)* TA and AA (Patients/Controls) OR (CI 95% CI) p
Gender
Female 22/37 1,00 (ref) 07/10 0,95 (0,27-3,32) 0,94
Male 126/130 1,00 (ref) 36/23 1,37 (0,68-2,75) 0,37
Age**
< 52 38/115 1,00 (ref) 14/25 1,08 (0,46- 2,51) 0,86
> 52 110/52 1,00 (ref) 29/08 1,30 (0,53- 3,16) 0,52
Cigarette smoking
No 14/87 1,00 (ref) 03/11 2,57 (0,52-12,83) 0,25
Yes 134/80 1,00 (ref) 40/22 1,19 (0,63-2,24) 0,59
Alcohol drinking
No 31/87 1,00 (ref) 11/11 2,23 (0,67 - 7,43) 0,19
Yes 32/80 1,00 (ref) 117/22 1,02 (0,51 -2,03) 0,96
*Adjusted for age, gender, cigarette smoking and alcoholic beverages drinking; OR = odds ratio; CI = confidence interval
** Group age median calculation
Table 4. Clinical and pathological characteristics and TAX1BP1 polymorphism (Genotypes TT: wild homozygote; TA: heterozygote; AA: poly-
morphic homozygote) 
Variables TT genotype OR (CI 95%) TA and AA genotypes OR (CI 95%)* p
Tumor sites**
Oral cavity 48 1,00 (ref) 23 2,38 (1,18 - 4,78) 0,01
Pharynx 48 1,00 (ref) 08 0,49 (0,21 - 1,15) 0,10
Larynx 48 1,00 (ref) 11 0,70 (0,32 - 1,52) 0,36
Tumor extension***
T1/T2 46 1,00 (ref) 14 1,12 (0,53 - 2,38) 0,77
T3/T4 89 1,00 (ref) 25 1,09 (0,52 - 2,31) 0,81
Lymph node involvement ***
No 74 1,00 (ref) 24 1,00 (ref)
Yes 67 1,00 (ref) 15 0,67 (0,32 - 1,40) 0,28
Stages ***
I/II 34 1,00 (ref) 11 1,00 (ref)
III/IV 94 1,00 (ref) 26 0,82 (0,36- 1,87) 0,65
*Adjusted for age, gender, cigarette smoking and alcoholic beverages drinking.
** Unknown primary anatomical sites were taken off.
*** Analysis carried out for patients with complete pathology data
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DISCUSSION
This study matched literature data regarding the 
epidemiology of head and neck cancer, which is more 
frequent in men after their fifth decades of life, smokers 
and those who drink alcoholic beverages. Epidemiologic 
evidence has shown that the incidence of head and neck 
cancer increases with age2,3.
Such disease is relatively rare in women; especially 
in developing countries, males are more affected than 
females1,26. Although this neoplasia preferably affects 
men, in recent years we have seen a notable increase in 
its incidence in women, which should reflect changes in 
smoking and drinking habbits9,10.
Regarding risk factors, smoking and drinking al-
coholic beverages are the main factors involved in the 
development of head and neck neoplasia - according to 
the literature8-10 and this study showed this association.
The genotypic frequencies are within the Hardy-
Weinberg balance.
The results did not show significant differences 
between the groups studied and the TAX1BP1 gene 
polymorphism, although there are studies correlating the 
presence of such gene and the neoplasm development, 
especially leukemias18,27. There are also gene expression 
studies showing increased TAX1BP1 gene expression in 
ovary cancer28 and rheumatoid arthritis29. It is known that 
the protein interacts with the A20 (anti-apoptotic activity). 
Such protein causes complex NF-KB activation, which in-
creases proliferation, cell death protection and eventually 
cell transformation, although these mechanisms are not 
well understood30.
The literature does not show any description of the 
frequencies of these polymorphisms and their respective 
effects on head and neck cancer, and there are no Brazi-
lian studies on this subject - which further highlights the 
importance of the present investigation.
The polymorphic allele frequency was greater in the 
oral cavity cancer and can be explained by the histological 
differences which are peculiar to the different anatomical 
regions. Other studies suggest that the biological beha-
vior of this tumor type is different in different anatomic 
locations31.
Numerous studies analyzed the association of 
clinical and pathological characteristics of patients with 
head and neck cancer and polymorphisms. As to tumor 
aggressiveness, in this study we did not notice association 
between this polymorphism and extension (T category) 
and tumor staging in the three major head and neck 
regions analyzed (oral cavity, pharynx and larynx). The 
study by Teng et al. in 200932, analyzed the relationship 
between SDF-1-30A and CXCR4 genes polymorphisms and 
showed a relation between the latter with advanced stage 
mouth tumors (III and IV). CYP1E1*5B and null GSTM1 
polymorphisms were also associated to advanced stages 
of the disease33.
The association of these polymorphisms and head 
and neck cancer, as well as their association with respon-
ses to carcinogens can help understand the mechanisms 
involved in the neoplastic process and the setting up of 
strategies to prevent this disease.
CONCLUSION
There is evidence of this association between the 
TAX1BP1 gene polymorphism and oral cavity cancer. 
There are no differences in the distribution of the poly-
morphism among patients with head and neck cancer 
and individuals without history of neoplasm. There was 
also no difference in genotype distribution between the 
different tumor sizes, lymph node involvement, staging, 
recurrence and death.
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